Sinovac Biotech reports progress in EV71 vaccine Phase III clinical trial

Sinovac Biotech announced a positive SFDA inspection of the three clinical trial sites being used in the Company's Phase III study of its proprietary inactivated Enterovirus 71 vaccine against hand, foot and mouth disease. In May, an expert from the Center for Drug Evaluation within the State Food and Drug Administration completed an inspection of the three Phase III study sites in Jiangsu Province, as well as the central laboratories set up by the Chinese Center for Disease Control and Prevention, according to the Good Clinical Practice guidelines.